Optimizing Care in Inflammatory Bowel Disease (IBD): The Role of Emerging Therapies in Improving Patient Outcomes

CME: 1.0

June 23, 2022
/ Print / Reprints /
| Share More
/ Text Size+

Target Audience

This educational activity is directed toward gastroenterologists, primary care clinicians, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with IBD.

Activity Overview

Although biologic agents helped usher in a new treatment paradigm for inflammatory bowel disease (IBD), appreciable rates of primary non-response, loss of response, and adverse reactions still require additional treatments. Clinical research has therefore focused on new therapeutic targets and modifications of existing ones to improve the response rates and safety/tolerability profile of IBD medications. Research has resulted in the development of small molecule drugs (SMDs) like selective JAK inhibitors and leukocyte trafficking/migrating inhibitors, and their emergence has created a need for educational activities that help clinicians navigate the ever-expanding clinical armamentarium.

This educational activity is an archive of the live symposium held on May 21, 2022.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Apply diagnostic criteria/algorithms toward an early diagnosis of IBD based on patient presentation
  • Select an approved therapy targeting IBD based on current clinical evidence and guidelines
  • Evaluate efficacy and safety of emerging therapies in the multimodal treatment approach to IBD
  • Develop collaborative multidisciplinary management strategies for long-term management of IBD

Post a comment to this article